keyword
MENU ▼
Read by QxMD icon Read
search

Platinum chemotherapy resistance

keyword
https://www.readbyqxmd.com/read/29156754/functional-characterization-of-a-novel-transcript-of-ercc1-in-chemotherapy-resistance-of-ovarian-cancer
#1
Jia Liu, Lin Zhang, Ping Mao, Guoqiang Jiang, Likun Liu, Jing Wang, Wei Yang, Lawrence Owusu, Weiling Li
Approximately 15-20% of ovarian cancer patients receiving platinum-based chemotherapy are primary platinum-resistant. Identification of these patients and transfer to other more effective therapy could reduce the morbidity of ovarian cancer. ERCC1 is a DNA repair gene which can complex with XPF to repair cisplatin-induced DNA damage and cause chemotherapy resistance. In this study, we found a novel ERCC1 transcript initiated upstream of the normal transcription initiation site. The expression of this larger ERCC1 transcript dramatically increased following cisplatin treatment in ovarian cancer cells and was regulated by the MAPK pathway...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29151973/roles-of-micrornas-in-the-resistance-to-platinum-based-chemotherapy-in-the-non-small-cell-lung-cancer
#2
REVIEW
Hongjing Zang, Jianlun Peng, Weiyuan Wang, Songqing Fan
Platinum-based adjuvant chemotherapy improves survival among patients with lung tumors, in particular non-small cell lung cancer (NSCLC). But the predicament of drug resistance in NSCLC patients is frustrating us. The profiles of microRNAs are different between platinum chemotherapy resistant and sensitive NSCLC cells. Researches regarding microRNAs and their targets, in platinum drug resistant cases, illuminate novel ideals for platinum-based chemotherapy for NSCLC patients. Therefore, in this review we will focus on three aspects: Epithelial-mesenchymal transition (EMT), cell proliferation and apoptosis, and the roles of microRNAs in cisplatin (CDDP) and carboplatin (CBP) resistance...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/29143497/detection-and-monitoring-of-driver-mutations-by-next-generation-sequencing-in-squamous-cell-lung-cancer-patient-and-possible-predictive-biomarker-of-third-generation-egfr-tyrosine-kinase-inhibitors
#3
Xiaoyan Shen, Jie Shen, Hang Zhang, Yuxin Cheng, Yang Yang, Jiahui Gao, Yu Zhang, Rutian Li, Baorui Liu, Lifeng Wang
Driver mutation detection and the development of targeted drugs have significantly improved survival of advanced lung adenocarcinoma patients with driver mutations. However, we still lack understanding of druggable mutations in patients with advanced squamous cell lung cancer (SQCLC). Less than 10% of SQCLC patients have EGFR gene mutations, thus we have limited knowledge of biological molecular changes with first generation EGFR-tyrosine kinase inhibitor (TKI) resistance. We report a case of an SQCLC patient treated with first-line platinum-doublet chemotherapy...
November 16, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/29143144/carcinosarcoma-of-the-ovary-compared-to-ovarian-high-grade-serous-carcinoma-impact-of-optimal-cytoreduction-and-standard-adjuvant-treatment
#4
Ibrahim Yalcin, Mehmet Mutlu Meydanli, Ahmet Taner Turan, Salih Taskin, Mustafa Erkan Sari, Tayfun Gungor, Ozgur Akbayir, Ali Ayhan
OBJECTIVE: The purpose of this retrospective study was to compare the prognoses of women with ovarian carcinosarcoma (OCS) who had optimal cytoreductive surgery followed by platinum plus taxane combination chemotherapy to those of women with ovarian high-grade serous carcinoma (HGSC) treated in the same manner. METHODS: A multicenter, retrospective department database review was performed to identify patients with OCS at eight gynecologic oncology centers in Turkey...
November 16, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29137078/successful-treatment-of-ovarian-cancer-with-apatinib-combined-with-chemotherapy-a-case-report
#5
Mingzi Zhang, Zhongkai Tian, Yehong Sun
RATIONALE: The standard treatment for ovarian cancer is chemotherapy with 2 drugs (taxanes and platinum drugs). However, the traditional combination of the 2 drugs has many adverse effects (AEs) and the cancer cells will quickly become resistant to the drugs. Apatinib is a small-molecule antiangiogenic agent which has shown promising therapeutic effects against diverse tumor types, but it still remains unknown whether apatinib has an antitumor effect in patients with ovarian cancer. Herein, we present a successfully treated case of ovarian cancer using chemotherapy and apatinib, in order to demonstrate the effectiveness of this new combined regimen in ovarian cancer...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29131211/pharmaco-genomic-investigations-of-organo-iridium-anticancer-complexes-reveal-novel-mechanism-of-action
#6
Jessica M Hearn, George M Hughes, Isolda Romero-Canelón, Alison F Munro, Belén Rubio-Ruiz, Zhe Liu, Neil O Carragher, Peter J Sadler
Resistance to platinum drugs (used in >50% of cancer chemotherapies) is a clinical problem. Other precious metal complexes with distinct mechanisms of action might overcome this. Half-sandwich organometallic complexes containing arene or cyclopentadienyl (Cp) ligands show promise. We screened two iridium(iii) complexes [Ir(Cp(Xbiph))(ppy)Cl] (ZL49, 1, ppy = phenylpyridine) and [Ir(Cp(Xph))(azpyNMe2)Cl]PF6 (ZL109, 2, azpyNMe2 = N,N-dimethylphenylazopyridine) in 916 cancer cell lines from 28 tissue types. On average, complex 2 was 78× more potent than 1, 36× more active than cisplatin (CDDP), and strongly active (nanomolar) in patient-derived ovarian cancer cell lines...
November 13, 2017: Metallomics: Integrated Biometal Science
https://www.readbyqxmd.com/read/29129398/genomic-markers-in-prostate-cancer-decision-making
#7
REVIEW
Vito Cucchiara, Matthew R Cooperberg, Marc Dall'Era, Daniel W Lin, Francesco Montorsi, Jack A Schalken, Christopher P Evans
CONTEXT: Although the widespread use of prostate-specific antigen (PSA) has led to an early detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA remains one of the most controversial biomarkers due to its limited specificity. As part of emerging efforts to improve both detection and management decision making, a number of new genomic tools have recently been developed. OBJECTIVE: This review summarizes the ability of genomic biomarkers to recognize men at high risk of developing PCa, discriminate clinically insignificant and aggressive tumors, and facilitate the selection of therapies in patients with advanced disease...
November 9, 2017: European Urology
https://www.readbyqxmd.com/read/29122777/genetic-predictors-of-response-to-systemic-therapy-in-esophagogastric-cancer
#8
Yelena Y Janjigian, Francisco Sanchez-Vega, Philip Jonsson, Walid K Chatila, Jaclyn F Hechtman, Geoffrey Y Ku, Jamie C Riches, Yaelle Tuvy, Ritika Kundra, Nancy Bouvier, Efsevia Vakiani, Jianjiong Gao, Zachary J Heins, Benjamin E Gross, David P Kelsen, Liying Zhang, Vivian E Strong, Mark Schattner, Hans Gerdes, Daniel G Coit, Manjit Bains, Zsofia K Stadler, Valerie W Rusch, David R Jones, Daniela Molena, Jinru Shia, Mark E Robson, Marinela Capanu, Sumit Middha, Ahmet Zehir, David M Hyman, Maurizio Scaltriti, Marc Ladanyi, Neal Rosen, David H Ilson, Michael F Berger, Laura Tang, Barry S Taylor, David B Solit, Nikolaus Schultz
The incidence of esophagogastric cancer is rapidly rising but only a minority of patients derive durable benefit from current therapies. Chemotherapy as well as anti-HER2 and PD-1 antibodies are standard treatments. To identify predictive biomarkers of drug sensitivity and mechanisms of resistance, we implemented prospective tumor sequencing of metastatic esophagogastric cancer patients. There was no association between HRD defects and response to platinum-based chemotherapy. Patients with MSI-H tumors were intrinsically resistant to chemotherapy but more likely to achieve durable responses to immunotherapy...
November 9, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/29121854/monitoring-interactions-inside-cells-by-advanced-spectroscopies-overview-of-copper-transporters-and-cisplatin
#9
Alessia Lasorsa, Giovanni Natile, Antonio Rosato, Francesco Tadini-Buoninsegni, Fabio Arnesano
BACKGROUND: Resistance, either at the onset of the treatment or developed after an initial positive response, is a major limitation of antitumor therapy. In the case of platinum-based drugs, copper transporters have been found to interfere with drug trafficking by facilitating the import or favoring the platinum export and inactivation. METHODS: The use of powerful spectroscopic, spectrometric and computational methods have allowed a deep structural insight into the mode of interaction of platinum drugs with the metal-binding domains of the transporter proteins...
November 10, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29121427/long-term-survival-with-bevacizumab-in-heavily-pretreated-and-platinum-resistant-mucinous-ovarian-cancer-a-case-report
#10
Yosuke Tarumi, Taisuke Mori, Hiroshi Matsushima, Tetsuya Kokabu, Hiroshi Tsuchiya, Jo Kitawaki
The prognosis of patients with recurrent and platinum-resistant ovarian cancer is quite poor. Randomized trials have shown that bevacizumab (BEV) can be effective, even in platinum-resistant ovarian cancer, but only a few such cases of long-term survival with BEV have been reported. Furthermore, there is no consensus on how many cycles of BEV should be administered. Herein, we report a case of refractory mucinous ovarian cancer showing long-term survival after six cycles of weekly paclitaxel with BEV followed by 26 cycles of BEV maintenance...
November 9, 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/29120085/novel-au-and-ag-carbene-complexes-exert-anti-tumor-effects-triggering-the-ros-dependent-intrinsic-apoptotic-pathway
#11
Domenico Iacopetta, Annaluisa Mariconda, Carmela Saturnino, Anna Caruso, Giuseppe Palma, Jessica Ceramella, Noemi Muià, Mariarita Perri, Maria Stefania Sinicropi, Maria Cristina Caroleo, Pasquale Longo
Cisplatin and other platinum-based drugs are well-known valid anticancer drugs. However, during the chemotherapy, the presence of numerous side effects and the onset of frequent phenomena of resistance pushes forward many research groups to devise new metal-based compounds holding improved anticancer properties and lower undesired effects. Amongst the variety of synthesized compounds, significant anti-proliferative effects were obtained employing organometallic compounds, particularly those based on silver or gold...
November 9, 2017: ChemMedChem
https://www.readbyqxmd.com/read/29118718/the-practice-of-physical-activity-in-the-setting-of-lower-extremities-sarcomas-a-first-step-toward-clinical-optimization
#12
Mohamad Assi, Mickael Ropars, Amélie Rébillard
Lower-extremities sarcoma patients, with bone tumor and soft-tissue sarcoma, are a unique population at high risk of physical dysfunction and chronic heart diseases. Thus, providing an adequate physical activity (PA) program constitutes a primary part of the adjuvant treatment, aiming to improve patients' quality of life. The main goal of this paper is to offer clear suggestions for clinicians regarding PA around the time between diagnosis and offered treatments. These preliminary recommendations reflect our interpretation of the clinical and preclinical data published on this topic, after a systematic search on the PubMed database...
2017: Frontiers in Physiology
https://www.readbyqxmd.com/read/29113212/knockdown-of-fuse-binding-protein-1-enhances-the-sensitivity-of-epithelial-ovarian-cancer-cells-to-carboplatin
#13
Jinli Zhang, Xifeng Xiong, Xing Hua, Wenjuan Cao, Shengnan Qin, Libing Dai, Peihong Liang, Huiling Zhang, Zhihe Liu
Epithelial ovarian cancer (EOC) affects almost 25,000 women annually and is the fifth most common malignancy in women in North America. A combination of surgery and cytotoxic chemotherapy may produce a favorable clinical response. The platinum-paclitaxel combination regimen is the chemotherapy gold-standard for advanced ovarian cancer, and carboplatin is one of the agents in this combination therapy. However, the majority of patients eventually experience a relapse due to the development of platinum resistance...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29108284/overexpression-of-mir-26b-decreases-the-cisplatin-resistance-in-laryngeal-cancer-by-targeting-atf2
#14
Linli Tian, Jiarui Zhang, Xiuxia Ren, Xinyu Liu, Wei Gao, Chen Zhang, Yanan Sun, Ming Liu
Cisplatin is a common used chemotherapeutic drug for the treatment of laryngeal cancer. However, drug-resistance is a major obstacle in platinum-based chemotherapy for laryngeal cancer. Recent studies have demonstrated that dysregulation of microRNAs (miRNAs) is responsible for chemoresistance in multiple cancers including laryngeal cancer, but the potential mechanisms are required to be explored. In the present study, we constantly exposed the laryngeal cancer cell line Hep-2 with cisplatin to establish a cisplatin-resistant laryngeal cancer cell model (Hep-2/R)...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29107348/validation-of-the-modified-glasgow-prognostic-score-mgps-in-recurrent-ovarian-cancer-roc-analysis-of-patients-enrolled-in-the-gcig-symptom-benefit-study-sbs
#15
Felicia T Roncolato, Dominique Berton-Rigaud, Rachel O'Connell, Anne Lanceley, Jalid Sehouli, Luke Buizen, Aikou Okamoto, Eriko Aotani, Domenica Lorusso, Paul Donnellan, Amit Oza, Elisabeth Avall-Lundqvist, Jonathan Berek, Felix Hilpert, Jonathan A Ledermann, Marie Christine Kaminsky, Martin R Stockler, Madeleine T King, Michael Friedlander
BACKGROUND: Modified Glasgow Prognostic Score (mGPS) is predictive of survival in many advanced cancers, but has not been evaluated in recurrent ovarian cancer (ROC). The aim was to determine validity of mGPS in ROC, investigate its associations with health related quality of life (HRQL) and ECOG performance status (PS). METHODS: mGPS is based on serum C reactive protein (CRP) and albumin, with scores ranging from 0 (least) to 2 (most). HRQL was measured with EORTC QLQ C-30 and OV-28...
October 26, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/29101033/potential-influence-of-interleukin-6-on-the-therapeutic-effect-of-gefitinib-in-patients-with-advanced-non-small-cell-lung-cancer-harbouring-egfr-mutations
#16
Tomoki Tamura, Yuka Kato, Kadoaki Ohashi, Kiichiro Ninomiya, Go Makimoto, Hiroko Gotoda, Toshio Kubo, Eiki Ichihara, Takehiro Tanaka, Koichi Ichimura, Yoshinobu Maeda, Katsuyuki Hotta, Katsuyuki Kiura
Although epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are a key therapy used for patients with EGFR-mutant non-small cell lung cancer (NSCLC), some of whom do not respond well to its therapy. Cytokine including IL-6 secreted by tumour cells is postulated as a potential mechanism for the primary resistance or low sensitivity to EGFR-TKIs. Fifty-two patients with advanced EGFR-mutant NSCLC who had received gefitinib were assessed retrospectively. The protein expression of IL-6 in the tumour cells was assessed by immunostaining and judged as positive if ≥ 50 of 100 tumour cells stained positively...
October 31, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29100359/the-conjugated-antimetabolite-5-fdu-ecyd-and-its-cellular-and-molecular-effects-on-platinum-sensitive-vs-resistant-ovarian-cancer-cells-in-vitro
#17
Sarah Schott, Pauline Wimberger, Barbara Klink, Konrad Grützmann, Julian Puppe, Ulrike Sophie Wauer, Daniel Martin Klotz, Evelin Schröck, Jan Dominik Kuhlmann
Background: Resistance to platinum-based chemotherapy is a clinical challenge in the treatment of ovarian cancer (OC) and limits survival. Therefore, innovative drugs against platinum-resistance are urgently needed. Our therapeutic concept is based on the conjugation of two chemotherapeutic compounds to a monotherapeutic pro-drug, which is taken up by cancer cells and cleaved into active cytostatic metabolites. We explore the activity of the duplex-prodrug 5-FdU-ECyd, covalently linking 2'-deoxy-5-fluorouridine (5-FdU) and 3'-C-ethynylcytidine (ECyd), on platinum-resistant OC cells...
September 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/29082457/systematic-analysis-reveals-a-lncrna-mrna-co-expression-network-associated-with-platinum-resistance-in-high-grade-serous-ovarian-cancer
#18
Lei Fang, Hao Wang, Peiling Li
Resistance to platinum-based chemotherapy is the major barrier to treating high-grade serous ovarian cancer (HGS-OvCa). To improve HGS-OvCa patient prognosis, it is critical to identify the underlying mechanisms that promote platinum resistance. The goal of the present study was to identify a lncRNA-mRNA co-expression network and key lncRNAs that predict resistance to platinum-based chemotherapy in ovarian cancer patients. By systematically analyzing the expression profiles of lncRNAs and mRNAs in HGS-OvCa samples from the Cancer Genome Atlas (TCGA), we revealed that lncRNAs play important roles in platinum resistance in HGS-OvCa patients and delineate a lncRNA-mRNA co-expression network in HGS-OvCa patients who exhibit platinum resistance...
October 30, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/29080971/combination-chemotherapy-with-irinotecan-and-gemcitabine-for-taxane-platinum-resistant-refractory-ovarian-and-primary-peritoneal-cancer-a-multicenter-phase-i-ii-trial-gogo-ov-6
#19
Kiyoshi Yoshino, Shoji Kamiura, Takeshi Yokoi, Ruriko Nakae, Masami Fujita, Masahiko Takemura, Kazushige Adachi, Akinori Wakimoto, Takamichi Nishizaki, Yasuhiko Shiki, Tateki Tsutsui, Yuki Kanda, Eiji Kobayashi, Kae Hashimoto, Seiji Mabuchi, Yutaka Ueda, Kenjiro Sawada, Takuji Tomimatsu, Tadashi Kimura
PURPOSE: To develop a new therapeutic strategy for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancers, we evaluated the feasibility and efficacy of irinotecan and gemcitabine combination chemotherapy. METHODS: Patients with taxane/platinum-resistant/refractory cancer received escalating doses of irinotecan and gemcitabine (level 1: 80 and 800 mg/m(2), respectively; level 2: 100 and 1000 mg/m(2)) on days 1 and 8 on a 21-day cycle. Genotyping for UGT1A1*6 and *28 polymorphisms was performed for possible adverse irinotecan sensitivity...
October 28, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29066771/therapeutic-potential-of-the-phosphino-cu-i-complex-hydrocup-in-the-treatment-of-solid-tumors
#20
Valentina Gandin, Cecilia Ceresa, Giovanni Esposito, Stefano Indraccolo, Marina Porchia, Francesco Tisato, Carlo Santini, Maura Pellei, Cristina Marzano
[Cu(thp)4][PF6] (HydroCuP) is a phosphino copper(I) complex highly soluble and stable in physiological media that has been developed as a possible viable alternative to platinum-based drugs for anticancer therapy. HydroCuP potently inhibited the growth of human cancer cells derived from solid tumors by inducing endoplasmatic reticulum (ER) stress thus leading to cell death through paraptosis with a preferential efficacy against cancer rather than non-cancer cells. Aim of the present study was to assess the therapeutic potential of HydroCuP in vivo, in syngenic and xenograft murine models of solid tumors by triggering the Unfolded Protein Response (UPR) pathway...
October 24, 2017: Scientific Reports
keyword
keyword
24024
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"